Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of SGB-3383 in Healthy Subjects
Sponsor: Suzhou Sanegene Bio Inc.
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3383 in healthy subjects. The study will be designed as a single ascending dose (SAD) phase, utilizing a double-blind, placebo-controlled approach.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3383 in Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
37
Start Date
2025-06
Completion Date
2027-01
Last Updated
2025-06-03
Healthy Volunteers
Yes
Conditions
Interventions
SGB-3383
SGB-3383 for sc injection, single dose
SGB-3383-Matching placebo
SC injection, single dose